Reply to López-Campos et al. and to Rogliani and Calzetta
- PMID: 33444510
- PMCID: PMC8017589
- DOI: 10.1164/rccm.202012-4484LE
Reply to López-Campos et al. and to Rogliani and Calzetta
Comment on
-
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC. Am J Respir Crit Care Med. 2021. PMID: 33252985 Free PMC article. Clinical Trial.
-
Mortality in ETHOS: A Question of "Power".Am J Respir Crit Care Med. 2021 Apr 1;203(7):926-927. doi: 10.1164/rccm.202012-4328LE. Am J Respir Crit Care Med. 2021. PMID: 33444515 Free PMC article. No abstract available.
References
-
- Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. ETHOS Investigators Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a randomized, double-blind, multi-center parallel-group study Am J Respir Crit Care Med[online ahead of print] 30 Nov 2020 - PubMed
-
- Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. ETHOS Investigators. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48. - PubMed
-
- Global Initiative for Chronic Obstructive Lung Disease 2021 report: global strategy for prevention, diagnosis and management of COPD Fontana, WI: Global Initiative for Chronic Obstructive Lung Disease; 2021[updated 2020 Nov 25; accessed 2020 Dec 21]. Available from: https://goldcopd.org/2021-gold-reports/
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
